Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sha Mi

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Molecular and Cellular Neurosciences|October 3, 2006
LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injuryBenxiu Ji, Mingwei Li, Wu-Tian Wu, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerveMelissa M Gresle, Yaou Liu, Trevor J Kilpatrick, et al.
Nature Neuroscience|February 18, 2004
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complexSha Mi, Xinhua Lee, Zhaohui Shao, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546Bin Ma, Lei Zhang, Lihong Sun, et al.
Neuron|February 8, 2005
TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regenerationZhaohui Shao, Jeffrey L Browning, Xinhua Lee, et al.
Mabs|January 14, 2020
Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding siteKarl J M Hanf, Joseph W Arndt, YuTing Liu, et al.
Nature Neuroscience|May 17, 2005
LINGO-1 negatively regulates myelination by oligodendrocytesSha Mi, Robert H Miller, Xinhua Lee, et al.
Annals of Neurology|April 1, 2009
Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cellsSha Mi, Robert H Miller, Wei Tang, et al.
Nature Medicine|October 2, 2007
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitisSha Mi, Bing Hu, Kyungmin Hahm, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Molecular and Cellular Neurosciences|October 3, 2006
LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injuryBenxiu Ji, Mingwei Li, Wu-Tian Wu, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerveMelissa M Gresle, Yaou Liu, Trevor J Kilpatrick, et al.
Nature Neuroscience|February 18, 2004
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complexSha Mi, Xinhua Lee, Zhaohui Shao, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546Bin Ma, Lei Zhang, Lihong Sun, et al.
Neuron|February 8, 2005
TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regenerationZhaohui Shao, Jeffrey L Browning, Xinhua Lee, et al.
Mabs|January 14, 2020
Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding siteKarl J M Hanf, Joseph W Arndt, YuTing Liu, et al.
Nature Neuroscience|May 17, 2005
LINGO-1 negatively regulates myelination by oligodendrocytesSha Mi, Robert H Miller, Xinhua Lee, et al.
Annals of Neurology|April 1, 2009
Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cellsSha Mi, Robert H Miller, Wei Tang, et al.
Nature Medicine|October 2, 2007
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitisSha Mi, Bing Hu, Kyungmin Hahm, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
Pageof 5